Company / Return on Equity (ROE)
Lilly (Eli) Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
77.8%
FY2025
5-year range
51.8% / 92.6%
FY2021-FY2025
Trend
+4.8%
vs FY2024
Sector context
#5 of 190
Health Care
What the data says
Among 190 Health Care companies, Lilly (Eli) is in the top 3% for return on equity (roe). Return on Equity (ROE) has fluctuated over the past 10 years, ranging from 19.5% in FY2016 to 319.1% in FY2019.
Based on SEC 10-K filings.
77.8% in FY2025 with a 5-year CAGR of +20.5%. Top quartile in the Health Care sector.
Improved from 51.8% to 77.8% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +19.6pp
- 5-Year Change
- +20.5pp
- 10-Year Change
- -
Sector benchmark
Top 3% in Health CareTop 3% of 190This company 77.8% Sector average -50.4%
▼
+254.2% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 4.8% year-over-year.
- Currently 128.2pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2019.
- Lowest return on equity (roe) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 1.02 (distress zone, below 1.8 threshold)
- Strong profit margin: 31.0%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 77.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 77.8% | +4.8% |
| FY2024 | 74.2% | +43.2% |
| FY2023 | 51.8% | -10.9% |
| FY2022 | 58.2% | -37.2% |
| FY2021 | 92.6% | +61.7% |
| FY2020 | 57.3% | -82.0% |
| FY2019 | 319.1% | +870.5% |
| FY2018 | 32.9% | +58.2% |
| FY2017 | 20.8% | +6.3% |
| FY2016 | 19.5% | +18.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026